AMARIN CORP PLC\UK Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value
AMARIN CORP PLC\UK (AMRN) had Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value of $700.00 thousand as of 2020-03-31, per its 10-Q filed 2020-04-30.
Discontinued › Notes
us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2020-04-30
- 2020-03-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $700.00K.
| Period end | Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value |
|---|---|
| 2020-03-31 | $700.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |